Teva Pharmaceutical Statistics
Total Valuation
Teva Pharmaceutical has a market cap or net worth of $41.41 billion. The enterprise value is $54.35 billion.
Important Dates
The last earnings date was Wednesday, April 29, 2026, before market open.
| Earnings Date | Apr 29, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Teva Pharmaceutical has 1.16 billion shares outstanding. The number of shares has increased by 2.93% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.16B |
| Shares Change (YoY) | +2.93% |
| Shares Change (QoQ) | +0.51% |
| Owned by Insiders (%) | 0.46% |
| Owned by Institutions (%) | 68.56% |
| Float | 1.08B |
Valuation Ratios
The trailing PE ratio is 26.56 and the forward PE ratio is 14.32. Teva Pharmaceutical's PEG ratio is 3.49.
| PE Ratio | 26.56 |
| Forward PE | 14.32 |
| PS Ratio | 2.37 |
| Forward PS | 2.40 |
| PB Ratio | 5.00 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 35.12 |
| P/OCF Ratio | 24.02 |
| PEG Ratio | 3.49 |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 10.86, with an EV/FCF ratio of 46.37.
| EV / Earnings | 34.73 |
| EV / Sales | 3.13 |
| EV / EBITDA | 10.86 |
| EV / EBIT | 13.57 |
| EV / FCF | 46.37 |
Financial Position
The company has a current ratio of 1.01, with a Debt / Equity ratio of 2.06.
| Current Ratio | 1.01 |
| Quick Ratio | 0.53 |
| Debt / Equity | 2.06 |
| Debt / EBITDA | 3.29 |
| Debt / FCF | 14.44 |
| Interest Coverage | 4.48 |
Financial Efficiency
Return on equity (ROE) is 21.60% and return on invested capital (ROIC) is 18.63%.
| Return on Equity (ROE) | 21.60% |
| Return on Assets (ROA) | 6.38% |
| Return on Invested Capital (ROIC) | 18.63% |
| Return on Capital Employed (ROCE) | 15.11% |
| Weighted Average Cost of Capital (WACC) | 7.59% |
| Revenue Per Employee | $511,016 |
| Profits Per Employee | $46,097 |
| Employee Count | 33,950 |
| Asset Turnover | 0.44 |
| Inventory Turnover | 2.59 |
Taxes
| Income Tax | -187.00M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +119.83% in the last 52 weeks. The beta is 0.86, so Teva Pharmaceutical's price volatility has been lower than the market average.
| Beta (5Y) | 0.86 |
| 52-Week Price Change | +119.83% |
| 50-Day Moving Average | 31.31 |
| 200-Day Moving Average | 26.07 |
| Relative Strength Index (RSI) | 71.03 |
| Average Volume (20 Days) | 6,191,963 |
Short Selling Information
The latest short interest is 29.74 million, so 2.57% of the outstanding shares have been sold short.
| Short Interest | 29.74M |
| Short Previous Month | 37.62M |
| Short % of Shares Out | 2.57% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 5.16 |
Income Statement
In the last 12 months, Teva Pharmaceutical had revenue of $17.35 billion and earned $1.57 billion in profits. Earnings per share was $1.34.
| Revenue | 17.35B |
| Gross Profit | 9.03B |
| Operating Income | 4.01B |
| Pretax Income | 1.38B |
| Net Income | 1.57B |
| EBITDA | 5.00B |
| EBIT | 4.01B |
| Earnings Per Share (EPS) | $1.34 |
Full Income StatementBalance Sheet
The company has $3.74 billion in cash and $16.93 billion in debt, with a net cash position of -$13.18 billion or -$11.32 per share.
| Cash & Cash Equivalents | 3.74B |
| Total Debt | 16.93B |
| Net Cash | -13.18B |
| Net Cash Per Share | -$11.32 |
| Equity (Book Value) | 8.23B |
| Book Value Per Share | 7.07 |
| Working Capital | 178.00M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $1.71 billion and capital expenditures -$542.00 million, giving a free cash flow of $1.17 billion.
| Operating Cash Flow | 1.71B |
| Capital Expenditures | -542.00M |
| Depreciation & Amortization | 997.00M |
| Net Borrowing | -469.00M |
| Free Cash Flow | 1.17B |
| FCF Per Share | $1.01 |
Full Cash Flow StatementMargins
Gross margin is 52.06%, with operating and profit margins of 23.09% and 9.02%.
| Gross Margin | 52.06% |
| Operating Margin | 23.09% |
| Pretax Margin | 7.95% |
| Profit Margin | 9.02% |
| EBITDA Margin | 28.84% |
| EBIT Margin | 23.09% |
| FCF Margin | 6.76% |
Dividends & Yields
Teva Pharmaceutical does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.93% |
| Shareholder Yield | -2.93% |
| Earnings Yield | 3.80% |
| FCF Yield | 2.85% |
Dividend DetailsAnalyst Forecast
The average price target for Teva Pharmaceutical is $41.75, which is 17.39% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $41.75 |
| Price Target Difference | 17.39% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
Stock Splits
The last stock split was on July 1, 2004. It was a forward split with a ratio of 2:1.
| Last Split Date | Jul 1, 2004 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Teva Pharmaceutical has an Altman Z-Score of 0.79 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.79 |
| Piotroski F-Score | 7 |
